|Videos|December 14, 2022
Interview with Syngene at CPHI in Frankfurt, Germany
Author(s)Syngene
KEY LEARNING OBJECTIVES
- Syngene is an end-to-end CRO/CDMO which offers standalone as well as integrated services for small molecules and biologics
- We not only have capabilities but also capacity to fulfil commercial manufacturing requirements
- We can be a innovation partner for niche areas as well as small biotech/pharma companies
Related Content
Trending on Pharmaceutical Technology
1
Pharma's AI ROI Problem Isn't a Tech Problem but a Qualification Problem
2
Danish Biotechs Attracting Investor Attention
3
Three Formats, One Platform: Halo's New Sterile Fill-Finish Line
4
CPHI Milan Adds Sustainability Summit and New AI, Cold Chain, and Labeling Zones to 2026 Agenda
5